TW289755B - - Google Patents

Info

Publication number
TW289755B
TW289755B TW082109528A TW82109528A TW289755B TW 289755 B TW289755 B TW 289755B TW 082109528 A TW082109528 A TW 082109528A TW 82109528 A TW82109528 A TW 82109528A TW 289755 B TW289755 B TW 289755B
Authority
TW
Taiwan
Application number
TW082109528A
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929224169A external-priority patent/GB9224169D0/en
Priority claimed from GB939302367A external-priority patent/GB9302367D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Application granted granted Critical
Publication of TW289755B publication Critical patent/TW289755B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
TW082109528A 1992-11-18 1993-11-15 TW289755B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929224169A GB9224169D0 (en) 1992-11-18 1992-11-18 Pharmaceutical compounds
GB939302367A GB9302367D0 (en) 1993-02-06 1993-02-06 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
TW289755B true TW289755B (zh) 1996-11-01

Family

ID=26301995

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082109528A TW289755B (zh) 1992-11-18 1993-11-15

Country Status (16)

Country Link
US (1) US5434160A (zh)
EP (2) EP0599514A3 (zh)
JP (1) JPH06199862A (zh)
KR (1) KR940011465A (zh)
CN (1) CN1040982C (zh)
AU (1) AU668602B2 (zh)
CA (1) CA2103203A1 (zh)
CO (1) CO4130335A1 (zh)
CZ (1) CZ243493A3 (zh)
FI (1) FI103727B1 (zh)
HU (1) HU9303261D0 (zh)
IL (1) IL107627A (zh)
NO (1) NO304890B1 (zh)
NZ (1) NZ250195A (zh)
PL (1) PL301059A1 (zh)
TW (1) TW289755B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds
FR2795071B1 (fr) * 1999-06-16 2001-07-27 Adir Nouveaux derives de carboxylate de 7-oxo-2,3,7,14- tetrahydro-1h-benzo[b]pyrano[3,2,h] acridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU781986B2 (en) 1999-11-05 2005-06-23 Cytovia, Inc. Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002092076A1 (en) 2001-05-16 2002-11-21 Cytovia, Inc. Substituted coumarins and quinolines as caspases activators
ES2337558T3 (es) 2001-05-16 2010-04-27 Cytovia, Inc. 4-h-cromenos sustituidos y analagos como activadores de caspasas e inductores de apoptosis y uso como agentes anticancerigenos.
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1513515A2 (en) 2002-05-16 2005-03-16 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
JP2005531566A (ja) * 2002-05-16 2005-10-20 サイトビア インコーポレイティッド カスパーゼ活性化剤およびアポトーシス誘導物質としての置換４−アリール−４ｈ−ピロロ［２，３−ｈ］クロメンおよび類似体ならびにそれらの使用
CA2579768A1 (en) 2004-09-09 2006-03-16 Howard Florey Institute Of Experimental Physiology And Medicine Enzyme inhibitors and uses thereof
US7843312B2 (en) * 2006-12-12 2010-11-30 Honeywell International Inc. Wireless control of security system with key-operated key fob
US8263775B2 (en) 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
EP2638026B1 (en) * 2010-11-12 2018-07-11 Deutsches Krebsforschungszentrum (DKFZ) Chromene derivatives and their analoga as wnt pathway antagonists
WO2023099589A1 (en) * 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Irap inhibitors for use in the treatment of inflammatory diseases
CN115028643B (zh) * 2022-06-10 2024-03-22 中国药科大学 吡喃并喹啉衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4243674A (en) * 1978-06-12 1981-01-06 Pfizer Inc. 9-Hydroxydibenzo[b,d]pyrans and intermediates therefore
JPS61502124A (ja) * 1984-05-09 1986-09-25 ジ　オ−ストラリアン　ナシヨナル　ユニヴア−シテイ− 免疫応答の調節方法
JP2631710B2 (ja) * 1988-08-16 1997-07-16 日本ヘキスト・マリオン・ルセル株式会社 ピラノ〔ｆ〕キノリノン誘導体及び該化合物を有効成分とする医薬組成物
US4931221A (en) * 1988-12-30 1990-06-05 Ppg Industries, Inc. Photochromic spiropyran compounds
US5284868A (en) * 1991-10-09 1994-02-08 Eli Lilly And Company Pharmaceutical compounds
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
NO934145L (no) 1994-05-19
FI103727B (fi) 1999-08-31
JPH06199862A (ja) 1994-07-19
IL107627A (en) 1997-04-15
CN1040982C (zh) 1998-12-02
EP1004584A2 (en) 2000-05-31
PL301059A1 (en) 1994-05-30
AU5067193A (en) 1994-06-02
NZ250195A (en) 1995-12-21
FI935065A0 (fi) 1993-11-16
IL107627A0 (en) 1994-02-27
CZ243493A3 (en) 1994-06-15
AU668602B2 (en) 1996-05-09
US5434160A (en) 1995-07-18
EP0599514A3 (en) 1994-07-06
EP0599514A2 (en) 1994-06-01
CA2103203A1 (en) 1994-05-19
CN1092072A (zh) 1994-09-14
NO934145D0 (no) 1993-11-16
KR940011465A (ko) 1994-06-21
FI935065A (fi) 1994-05-19
NO304890B1 (no) 1999-03-01
CO4130335A1 (es) 1995-02-13
HU9303261D0 (en) 1994-03-28
EP1004584A3 (en) 2000-07-05
FI103727B1 (fi) 1999-08-31

Similar Documents

Publication Publication Date Title
EP0560570A3 (zh)
TW243465B (zh)
TW289755B (zh)
DE9200240U1 (zh)
DE9200319U1 (zh)
DE9200121U1 (zh)
DE9200245U1 (zh)
DE9200339U1 (zh)
DE9300648U1 (zh)
DE9200093U1 (zh)
DE9200022U1 (zh)
DE9200200U1 (zh)
DE9200371U1 (zh)
DE9200593U1 (zh)
DE9200040U1 (zh)
DE9200320U1 (zh)
DE9200242U1 (zh)
DE9200148U1 (zh)
DE9200325U1 (zh)
DE9200293U1 (zh)
DE9200211U1 (zh)
DE9200201U1 (zh)
DE9200313U1 (zh)
DE9200223U1 (zh)
BRPI9204323A2 (zh)